| |
Presentation |
Media |
|
Interview with Johan Sandin (CSO) in Aktiespararna’s analysis guide
|
|
|
|
Alzecure: CEO Martin Jönsson presents at Redeye Life Science Day 2020, December 1 2020.
|
|
|
|
Scientific presentation on the NeuroRestore® candidate ACD856 presented at the CTAD conference, 4-7 November, 2020.
|
|
|
|
Scientific presentation on Alzstatin presented at the CTAD conference, 4-7 November, 2020
|
|
|
|
Scientific and market update with professor Henrik Zetterberg on Alzheimer’s disease, bio-markers, potential future treatments, including Alzstatin and AlzeCure – September 30, 2020
|
|
|
|
AlzeCure presentation with CEO Martin Jönsson at Aktiespararna (Swedish) – September 8, 2020
|
|
|
|
AlzeCure Science & Market update about Alzheimer’s diseas and NeuroRestore (Swedish) – 1 september, 2020
|
|
|
|
Welcome to AlzeCure … Introduction film about the company (Swedish) – 1 minute
|
|
|
|
CEO presentation at the annual meeting (Swedish) – May 20, 2020
|
|
|
|
Get to know AlzeCure’s CEO Martin Jönsson – Redeye interview (Swedish) – March 19, 2020
|
|
|
|
AlzeCure presentation with CEO Martin Jönsson at Aktiespararna (Swedish) – March 16, 2020
|
|
|
|
About the Alzstatin® project Disease modifying treatment of Alzheimer’s disease
|
|
|
|
About Alzheimers disease
|
|
|
|
About the project NeuroRestore®, symptomatic treatment of cognitive disorders such as in Alzheimer’s disease
|
|
|
|
Scientific presentation about ACD856, a positive modulator of neurotrophin signaling reverses scopolamine- or age-induced cognitive deficits – March 2020
|
|
|
